AgelessRx
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Participants will be assigned to one of three groups: 1) control, 2) microdosed sublingual semaglutide, 3) microdosed subcutaneous semaglutide. At baseline and every 4 weeks thereafter, participants will be asked to complete surveys on health, wellness, mood, demographic information, and similar. Additionally, at baseline and every 12 weeks thereafter, they will be requested to complete evaluative blood work to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium). From baseline throughout the duration of the study, participants will…
Inclusion Criteria: * New or existing AgelessRx patient * Adults (aged 18-65) * Any sex * Any ethnicity * BMI ≥ 20 kg/m\^2 * Interest in taking microdoses of semaglutide for health and longevity improvement with no intent to seek weight loss improvement. Exclusion Criteria: * Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s) * History of bariatric surgery * Use of other weight-loss medications currently or within the past 6 months * Contraindications to semaglutide * Significant p…
Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.
Sublingual Placebo (weekly) for up to 6 months
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.